Literature DB >> 27566088

Monitoring of L-Arginine and Endogenous Dimethylarginines in Survivor Septic Patients - A Pilot Study.

Balázs Németh1, István Kiss2, Iván Péter3, Zénó Ajtay4, Ádám Németh5, László Márk6, Attila Csorba7, Tamás Kőszegi8, Diána Mühl9, Péter Kustán10.   

Abstract

BACKGROUND/AIM: Nitric oxide (NO) pathway plays a major role in the development and advancement of inflammation. We aimed to design a study and investigate its feasibility to show the changes of L-arginine, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), which are important regulators of the NO pathway. PATIENTS AND METHODS: Concentrations of L-arginine, ADMA and SDMA were measured by liquid chromatography-tandem mass spectrometry. Seventeen septic survival patients were enrolled and blood samples were obtained on the first, third and fifth day after the diagnosis of sepsis. Sixteen non-septic matched controls were recruited.
RESULTS: ADMA levels on admission correlated well with sequential organ failure assessment (SOFA) score. During the follow-up, L-arginine/ADMA ratio increased significantly from day 1 to day 3 (p=0.005), then decreased from day 3 to day 5 (p=0.023).
CONCLUSION: This study design seems feasible to investigate changes of L-Arginine, ADMA and SDMA in sepsis survival patients.
Copyright © 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  L-arginine; Sepsis; asymmetric dimethylarginine; nitric oxide; survival

Mesh:

Substances:

Year:  2016        PMID: 27566088

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  3 in total

1.  A Therapeutic Extracorporeal Device for Specific Removal of Pathologic Asymmetric Dimethylarginine from the Blood.

Authors:  Young Lee; Sarah M L Steinbach; David Basile; Jaipal Singh
Journal:  Blood Purif       Date:  2022-03-04       Impact factor: 3.348

2.  Angiotensin-converting Enzyme Inhibition Improves the Effectiveness of Transcutaneous Carbon Dioxide Treatment.

Authors:  Balazs Nemeth; Istvan Kiss; Timea Jencsik; Ivan Peter; Zita Kreska; Tamas Koszegi; Attila Miseta; Peter Kustan; Imre Boncz; Andrea Laczo; Zeno Ajtay
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

Review 3.  A new perspective on NO pathway in sepsis and ADMA lowering as a potential therapeutic approach.

Authors:  Jaipal Singh; Young Lee; John A Kellum
Journal:  Crit Care       Date:  2022-08-12       Impact factor: 19.334

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.